[Fibrates therapy: Rational use fenofibrate 2016. Executive summary]

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Cardiovascular disease prevention requires managing lipid factors beyond LDL cholesterol.
• Atherogenic dyslipidemia, including abnormal triglycerides and HDL cholesterol, necessitates specific treatment strategies.
• Patients with diabetes mellitus, metabolic syndrome, or obesity often present complex lipid profiles.

Purpose of the Study:

• To review the efficacy and safety of combining statins with fibrates for comprehensive dyslipidemia management.
• To provide guidance on controlling and monitoring lipid-lowering treatments.
• To highlight non-lipid-lowering benefits of fenofibrate.

Main Methods:

• Systematic review of data on statin-fibrate combination therapy.
• Analysis of safety and efficacy profiles.
• Inclusion of evidence on fenofibrate's additional therapeutic effects.

Main Results:

• Statin-fibrate combinations are often necessary for total dyslipidemia control in high-risk patients.
• The combination therapy demonstrates efficacy and safety in managing complex lipid profiles.
• Fenofibrate provides benefits independent of its lipid-modifying actions.

Conclusions:

• Comprehensive cardiovascular protection involves addressing atherogenic dyslipidemia alongside LDL cholesterol management.
• Statin-fibrate combinations are a valuable therapeutic option for patients with metabolic disorders.
• Further consideration of fenofibrate's multifaceted benefits is warranted in clinical practice.